We narrowed to 124 results for: ache

#137955-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.iAChSnFR (#137955). In addition to the viral particles, you will also receive purified pAAV.CAG.iAChSnFR plasmid DNA. CAG-driven iAChSnFR acetylcholine sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Borden et al bioRxiv 2020

Oct. 28, 2021

Academic Institutions and Nonprofits only

#137950-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynap.iAChSnFR (#137950). In addition to the viral particles, you will also receive purified pAAV.hSynap.iAChSnFR plasmid DNA. Synapsin-driven, iAChSnFR acetylcholine sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Borden et al bioRxiv 2020

Sept. 15, 2021

Academic Institutions and Nonprofits only

#121922-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_ACh3.0 (#121922). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_ACh3.0 plasmid DNA. Syn-driven expression of the genetically-encoded fluorescent acethycholine(ACh) sensor GRAB-ACh3.0. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Jing et al Nat Methods. 2020 Sep 28. pii: 10.1038/s

June 21, 2024

Academic Institutions and Nonprofits only

#60658-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1α-F-FLEX-mNaChBac-T2A-tdTomato (#60658). In addition to the viral particles, you will also receive purified pAAV-EF1α-F-FLEX-mNaChBac-T2A-tdTomato plasmid DNA. CAG-driven, Flp-dependent expression of the voltage-gated Na+ channel mNaChBac-T2A-tdTomato. These AAV preparations are suitable purity for injection into animals.

Massimo Scanziani

Xue et al Nature. 2014 Jul 31;511(7511):596-600. d

Oct. 21, 2024

Academic Institutions and Nonprofits only

#26966-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#26966-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

April 6, 2018

Academic Institutions and Nonprofits only

#131000-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-mScarlet (#131000). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-mScarlet plasmid DNA. CamKIIa-driven expression of mScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2023

Academic Institutions and Nonprofits only

#131001-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-mScarlet (#131001). In addition to the viral particles, you will also receive purified pAAV-hSyn-mScarlet plasmid DNA. Synapsin-driven mScarlet control vector. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Nov. 29, 2021

Academic Institutions and Nonprofits only

#124364-AAV2

Ready-to-use AAV2 particles produced from pAAV-FLEX-DTR-GFP (#124364). In addition to the viral particles, you will also receive purified pAAV-FLEX-DTR-GFP plasmid DNA. CBA-driven, Cre-dependent expression of DTR-GFP. These AAV preparations are suitable purity for injection into animals.

Eiman Azim, Thomas Jessell

Azim et al Nature. 2014 Apr 17;508(7496):357-63. do

June 16, 2020

Academic Institutions and Nonprofits only

#26966-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#131001-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-mScarlet (#131001). In addition to the viral particles, you will also receive purified pAAV-hSyn-mScarlet plasmid DNA. Synapsin-driven mScarlet control vector. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2023

Academic Institutions and Nonprofits only

#209658-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAGFLEX.(cyto).cpSFGFP.HaloTag (#209658). In addition to the viral particles, you will also receive purified pAAV.CAGFLEX.(cyto).cpSFGFP.HaloTag plasmid DNA. CAG-driven, Cre-dependent expression of cpSFGFP.HaloTag (non-responsive control). These AAV preparations are suitable purity for injection into animals.

Tim Brown, HHMI-JRC Tool Translation Team

Marvin et al Proc Natl Acad Sci U S A. 2024 May 21;12

Oct. 29, 2025

Academic Institutions and Nonprofits only

#131002-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Nov. 29, 2021

Academic Institutions and Nonprofits only

#131002-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2024

Academic Institutions and Nonprofits only

#209655-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag (#209655). In addition to the viral particles, you will also receive purified pAAV.CAGFLEX.(cyto).iATPSnFR2.S29W.A95K.HaloTag plasmid DNA. CAG-driven, Cre-dependent expression of the high affinity ATP biosensor iATPSnFR2. These AAV preparations are suitable purity for injection into animals.

Tim Brown, HHMI-JRC Tool Translation Team

Marvin et al Proc Natl Acad Sci U S A. 2024 May 21;12

Oct. 21, 2024

Academic Institutions and Nonprofits only

#106192-AAV1

Ready-to-use AAV1 particles produced from pAAV.GFAP.SF-iGluSnFR.A184S (#106192). In addition to the viral particles, you will also receive purified pAAV.GFAP.SF-iGluSnFR.A184S plasmid DNA. GFAP-driven expression of SF-iGluSnFR.A184S. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Sept. 11, 2020

Academic Institutions and Nonprofits only

#130995-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-ChRmine-mScarlet-Kv2.1-WPRE (#130995). In addition to the viral particles, you will also receive purified pAAV-hSyn-ChRmine-mScarlet-Kv2.1-WPRE plasmid DNA. hSyn-driven, soma-targeted ChRmine-mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Jan. 6, 2022

Academic Institutions and Nonprofits only

#130991-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-ChRmine-mScarlet-Kv2.1-WPRE (#130991). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-ChRmine-mScarlet-Kv2.1-WPRE plasmid DNA. CamKIIa-driven, soma-targeted ChRmine-mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Jan. 6, 2022

Academic Institutions and Nonprofits only

#130998-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE (#130998). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-ChRmine-mScarlet-WPRE plasmid DNA. Ef1a-driven, Cre-dependent expression of ChRmine-mScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2024

Academic Institutions and Nonprofits only

#71760-AAV1

Ready-to-use AAV1 particles produced from pAAV hSyn FLEx mGFP-2A-Synaptophysin-mRuby (#71760). In addition to the viral particles, you will also receive purified pAAV hSyn FLEx mGFP-2A-Synaptophysin-mRuby plasmid DNA. Syn-driven, Cre-dependent expression of membrane-bound GFP and the presynaptic protein synaptophysin fused to mRuby. These AAV preparations are suitable purity for injection into animals.

Liqun Luo

Beier et al Cell. 2015 Jul 30;162(3):622-34. doi: 10

May 5, 2021

Academic Institutions and Nonprofits only